How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/egfr-mutation-positive-unresectable-or-recurrent-non-small-cell-lung-cancer.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Vizimpro	dacomitinib	Pfizer		Epidermal growth factor receptor		2018-01-01
dacomitinib hydrate	dacomitinib-hydrate	Pfizer Inc.	The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose sho	Cyclin-G-associated kinase, Receptor-interacting serine/threonine-protein kinase 2, Receptor-interacting serine/threonine-protein kinase 3

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer Inc. · 2 drugs in EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer
Pfizer · 1 drug in EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer:

Cite this brief

Drug Landscape (2026). EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/egfr-mutation-positive-unresectable-or-recurrent-non-small-cell-lung-cancer. Accessed 2026-06-10.

EGFR mutation-positive, unresectable or recurrent non-small cell lung cancer full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing